Results 191 to 200 of about 4,506,026 (263)

TLR7 Agonist Nanomedicine Suppresses Lung Metastasis of Osteosarcoma by Remodeling the Immune Microenvironment

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
In tail‐vein and orthotopic osteosarcoma mouse models, 1V209‑Cho‑Lip, a TLR7 agonist liposome, effectively suppresses pulmonary metastasis and prolongs survival. Flow cytometry and single‑cell transcriptomics reveal that 1V209‑Cho‑Lip remodels both the pre‑metastatic and post‑metastatic immune microenvironments, alleviates myeloid‑mediated ...
Xinyue Zhang   +5 more
wiley   +1 more source

Reduced Type-I Interferon by Plasmacytoid Dendritic Cells and Asthma in School-Aged Children. [PDF]

open access: yesAllergy
Coenen I   +14 more
europepmc   +1 more source

Organ‐Specific Cancer‐Associated Fibroblast Subtypes Across the Digestive System Linked to Cancer Hallmarks

open access: yesCancer Science, Volume 117, Issue 9, Page 2496-2508, September 2026.
We integrated 14 single‐cell RNA‐seq datasets and 18 bulk cohorts to define eight CAF subtypes in GI cancers. myCAF1 and myCAF2 promoted immunosuppressive, poor‐prognosis niches, whereas iCAF1 was linked to favorable prognosis and antitumor immunity.
Huaitao Wang   +7 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, Volume 293, Issue 17, Page 5121-5139, September 2026.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

Publisher Correction: TNF and type I interferon crosstalk controls the fate and function of plasmacytoid dendritic cells. [PDF]

open access: yesNat Immunol
Arroyo Hornero R   +7 more
europepmc   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1481-1489, September 2026.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth   +8 more
wiley   +1 more source

The Role of Plasmacytoid Dendritic Cells in the Immune Contexture of <i>TP53</i>-Mutated High-Grade Serous Ovarian Cancer. [PDF]

open access: yesCancers (Basel)
Steger K   +9 more
europepmc   +1 more source

COMIP‐002: 27‐color flow cytometry for measurable residual disease detection in B‐cell lymphoblastic leukemia

open access: yes
Cytometry Part B: Clinical Cytometry, Volume 110, Issue 5, Page 321-325, September 2026.
Ryan C. Shean   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy